ClinicalTrials.gg
Not yet recruitingNCT07458230NGSUpdated Nov 5, 2026

Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation:

A Phase 3 interventional study of NGS diagnostic findings in Next Generation Sequencing (NGS), Surgical Site Infection (SSI) and Fracture Fixation, sponsored by Johns Hopkins Bloomberg School of Public Health. Not yet recruiting at 18 sites in United States. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Johns Hopkins Bloomberg School of Public Health · Phase 3, Interventional, and Treatment

How we know

Updated Nov 5, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 202 studies in Surgical Wound Infection with a site in United States — 31 open to participants now, 34 under way, 4 of them phase 3. Surgical Wound Infection · United States.

Planned enrollment
79th of 177
250 · median 208
Started
2027
the only one that year
Phase 3
30 of 202
4 open now
Primary completion
2028-10
later than 29 of 33 live
Registered
197th of 202
by date

Among the 202 studies in Surgical Wound Infection with a site in United States, this one is the 79th largest by planned enrollment of the 177 interventional ones that give a count, is the only one that started in 2027, is one of 30 in phase 3, reaches primary completion later than 29 of the 33 other live ones, and was the 197th registered.

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

31 of the 202 studies in Surgical Wound Infection with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies in Surgical Wound Infection with a site in United States, or all of them as a file.
02

Study summary

The study focuses on the serious problem of infections and wound-healing issues that can happen after high-energy bone fractures. These complications are common and can affect between 10% and 60% of patients, especially those with severe injuries. When a fracture is repaired with surgery and an infection develops afterward, patients often face long recovery times, more pain, and sometimes multiple surgeries. In the worst cases, the infection can lead to permanent disability or even amputation. The current standard test used in hospitals, called a culture, often misses certain bacteria, which can make treatment less effective. Because of this, the study aims to find out whether adding a newer test called Next Generation Sequencing (NGS) can help doctors identify infections more accurately and improve patient outcomes.

The main goal of the study is to see whether using NGS along with standard hospital cultures reduces the number of treatment failures compared to using standard cultures alone. Treatment failure means the infection does not get better and the patient must return to the operating room. The study also wants to learn whether NGS helps doctors make better antibiotic choices and avoid unnecessary or ineffective treatments. Another goal is to understand which NGS results are most helpful when doctors decide to change a patient's antibiotics. By learning this, researchers hope to create a model that explains how NGS information influences treatment decisions.

To join the study, patients must be between 18 and 84 years old and have a deep infection after a fracture was repaired with internal fixation, such as plates, screws, or rods. Patients must also meet infection criteria from either the Fracture-Related Infection (FRI) guidelines or the CDC's infection criteria. A total of 250 patients will be randomly placed into one of two groups: one group will receive treatment guided by both NGS and standard cultures, while the other group will receive treatment based only on standard cultures. Researchers will then compare how often treatment fails in each group.

Treatment failure includes several possible outcomes. The most important is an unplanned return to the operating room because the infection did not improve. Other types of failure include new superficial infections that do not require surgery, bones that fail to heal properly (called nonunion), amputation, and complications caused by antibiotics. Patients will return for follow-up visits at 2 weeks, 6 weeks, 3 months, 6 months, and 12 months after joining the study so researchers can track the patient's progress and monitor for any problems.

Right now, the failure rate for treating these infections using standard hospital cultures is about 30%, which is considered unacceptably high. The researchers believe that adding NGS will help lower this number because NGS can detect more types of bacteria, including ones that are hard to grow in a lab. With better information, doctors can choose antibiotics that are more likely to work the first time, which may reduce the need for additional surgeries and improve healing. This could be especially important for military service members, who often suffer high-energy injuries and face a greater risk of long-term complications if treatment fails.

NGS is already available, covered by Medicare, and fast enough to be useful in real-time medical decisions. If this study shows that NGS improves treatment outcomes, hospitals could begin using it widely and quickly. The researchers hope that this approach will lead to fewer infections, better antibiotic use, faster recovery, and improved long-term function for patients.

03

Conditions studied

  • Next Generation Sequencing (NGS)
  • Surgical Site Infection (SSI)
  • Fracture Fixation

Keywords

  • Next Generation Sequencing (NGS)
04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-84 years
  • History of extremity fracture proximal to the metatarsals and carpal bones treated with any type of internal fixation. Note that both healed and unhealed fractures are eligible.
  • Deep infection requiring surgery after fracture fixation as determined by either of the following:

FRI confirmatory criteria CDC criteria (without the timeframe). This includes the possibility of culture negative infection but determined to be infection by treatment team.

  • Plan for treatment includes antibiotic therapy prescribed by Infectious Disease provider(s), regardless of SOCHB culture or NGS results.

Exclusion criteria

Exclusion Criteria:

  • Spine fractures
  • High risk of amputation based on the initial managing physician opinion
  • Incarcerated/institutionalized
  • Patient is too sick to have surgery, i.e., medical co-morbidities which preclude treatment with a general anesthetic
  • Prior history of chronic infection at the surgical site
  • Pathological fractures from a neoplastic process
  • History of Paget's Disease
  • Unavailable for the planned 12 months of follow-up (e.g., planned follow-up at a location other than one of the study sites)
  • Extremity fracture occurred more than 2 years prior to the hospital admission for the presenting infection
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
250 participants (estimated)

Study arms

  • No intervention
    Standard of Care (Control)

    Participants in this group will receive standard of care treatment for FRI. The care team will Not be provided with NGS data. Treatment strategy will be entirely based on SOCHB culture assessment strategies.

  • Experimental
    Diagnostic Test: NGS diagnostic findings

    Patient will receive antibiotic treatment and course using the NGS results. The clinical care team will be provided with NGS diagnostic findings along with SOCHB culture data.

    Diagnostic Test: NGS diagnostic findings

Interventions

  • Diagnostic testNGS diagnostic findings

    Patient will receive antibiotic treatment and course using the NGS results. the investigators will require antibiotic treatment of any NGS finding that is not treated based on the results of SOCHB culture alone. Site PIs have agreed to integrate NGS results into the treatment plan. If the antibiotic plan contradicts the NGS-based results, alternative antibiotic selection and reason (e.g., allergy to an antibiotic, cost-prohibitive) will be documented in specific CRFs. All other treatments will be per SOC.

06

What researchers measure

Primary outcomes

  1. Infection treatment failure rate

    Infection treatment failure rate, defined as unplanned return to the operating room for infection after randomization. Infection at this time will be similarly defined as in the inclusion criteria, namely FRI confirmatory criteria and/or, CDC criteria (without the timeframe). This includes the possibility of culture negative infection but determined to be infection by the treatment team.

    Time frame: 12 month

07

Study locations

18 sites
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Oct 2028, 21 months later.

Of 38 phase 3 interventional studies under Surgical Wound Infection, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's planned 21 months is below that.

Start moved twice since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, last on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 9, 2026
StartEst.
Jan 1, 2027was Oct 2026
Primary completionEst.
Oct 1, 2028
CompletionEst.
Oct 1, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Jan 1, 2027
moved 2 times, Oct 8, 2026 – Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    Start date Nov 1, 2026→Jan 1, 2027
    + 1 other change: verification date
  2. Oct 8, 2026
    Start date Oct 1, 2026→Nov 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07458230
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Research Project Director
Contact
schung60@jhu.edu
317-944-9400
Clinical Research Manager
Contact
acarlini@jhu.edu
317-944-9400
Roman M Natoli, MD
principal investigator · Indiana University, Methodist Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion